Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer-Reference-Cited by-同舟云学术

Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer

Published:2008-12 Issue:3 Volume:111 Page:530-532
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Hamilton Chad A.,Maxwell G. Larry,Chernofsky Mildred R.,Bernstein Sarah A.,Farley John H.,Rose G. Scott

Publisher

Elsevier BV

Subject

Obstetrics and Gynaecology,Oncology

Reference15 articles.

1. Palliation of malignant ascites;Rosenberg;Gastroenterol Clin North Am,2006

2. Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer;Hu;Am J Pathol,2002

3. Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model;Hu;Clin Cancer Res,2005

4. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease;Kraft;Cancer,1999

5. Open-label safety and efficacy pilot trial of intraperitoneal bevacizumab as palliative treatment in refractory malignant ascites;El-Shami;J Clin Oncol,2007

Cited by 79 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of the combined use of docetaxel, cisplatin and apatinib mesylate on serum tumor markers and prognosis in advanced ovarian cancer patients;Tropical Journal of Pharmaceutical Research;2024-04-14

2. Malignant ascites: Current therapy options and treatment prospects;Cancer Treatment Reviews;2023-12

3. Predicting Tumour Progression of ID-8 Syngeneic Mouse Ovarian Cancer with Blood Biomarkers of CA-125, IL-6 and VEGF: A Prospective Laboratory-Based Study;Clinical and Experimental Obstetrics & Gynecology;2023-10-16

4. Intraperitoneal infusion of recombinant human endostatin improves prognosis in gastric cancer ascites;Future Oncology;2022-03

5. Estimating Treatment-Switching Bias in a Randomized Clinical Trial of Ovarian Cancer Treatment: Combining Causal Inference with Decision-Analytic Modeling;Medical Decision Making;2021-10-20